BioNTech to terminate mid-stage trial of mRNA cancer vaccine

BNTX•2026-08-28

Trial termination announced

BioNTech SE said on Friday it has decided to terminate the mid-stage trial of its experimental mRNA-based cancer vaccine in patients with a type of colorectal cancer.

U.S. listed shares of the company fell nearly 10% in premarket trading.

BioNTech to terminate mid-stage trial of mRNA cancer vaccine

Trial termination announced

Related News

Warsh says Fed has 'work to do' if above-target inflation persists

Intrusion completes purchase of remaining 40% of OW Cyber for $1.3 million cash

In-Line Dollar General Corporation <DG.N>: Morgan Stanley Raises Target Price to $145.00 From $132.00

Cosmos Health retires $8 million senior secured convertible note ahead of maturity

Cohen & Steers fund manager Anthony Puma discloses 2.92% stake in Prologis